DCF — CARLE BROMENN MEDICAL CENTER
Enterprise Value: $-347.2M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-347.2M
Enterprise Value
$-109.8M
PV of Cash Flows
$-237.5M
PV of Terminal Value
$-382.4M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $215.4M | $-21.7M | -10.0% | $-30.8M | $-28.0M |
| Year 2 | $221.9M | $-20.1M | -9.0% | $-29.5M | $-24.4M |
| Year 3 | $228.5M | $-18.4M | -8.0% | $-28.1M | $-21.1M |
| Year 4 | $235.4M | $-17.8M | -8.0% | $-27.8M | $-19.0M |
| Year 5 | $242.4M | $-17.7M | -7.0% | $-28.0M | $-17.4M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-347.2M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$209.1M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.10558672742374553
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5